Print（PDF/145KB） Jan. 17, 2025 Corporate
Sumitomo Pharma Announces Organizational Realignment and Personnel Changes
Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura) today announced the following organizational realignment and personnel changes, effective February 1, 2025.
I. Organizational Realignment (effective February 1, 2025)
Corporate Departments
As announced on December 17, 2024, following the establishment of RACTHERA Co., Ltd., a joint venture for regenerative medicine and cell therapy business with Sumitomo Chemical Co., Ltd. (company split (simplified absorption-type company split) and transfer of subsidiary shares), Sumitomo Pharma's organizations related to regenerative medicine and cell therapy business (Regenerative & Cellular Medicine Office, Regenerative & Cellular Medicine Kobe Center, Regenerative & Cellular Medicine Manufacturing Plant) will be reorganized and transferred to RACTHERA and S-RACMO Co., Ltd., a joint venture between Sumitomo Pharma and Sumitomo Chemical. In line with the transfer, Regenerative Medicine Office is created in Sumitomo Pharma as a department to maximize the leverages of the Sumitomo Pharma’s technologies and knowledge in the field of regenerative and cellular medicine and to promote collaboration with affiliated companies.
II. Changes in Personnel (effective February 1, 2025)
Corporate Departments
| Position as of February 1, 2025 | Current position | Name |
|---|---|---|
| External Affairs; Corporate Governance; IT Management & Data Analytics Vice President, Head of External Affairs |
Regenerative & Cellular Medicine Office; Regenerative & Cellular Medicine Kobe
Center; Regenerative & Cellular Medicine Manufacturing Plant; External Affairs; Corporate Governance; IT Management & Data Analytics Vice President, Head of External Affairs Vice President, Head of Regenerative & Cellular Medicine Office |
Tomokazu Nagano |
| Representative Director, President and CEO, RACTHERA Co., Ltd.Corporate Officer, Regenerative Medicine Office | Vice President, Head of Regenerative & Cellular Medicine Kobe Center | Atsushi Ikeda |
| Representative Director, President and CEO, S-RACMO Co., Ltd.Corporate Officer, Regenerative Medicine Collaboration | Representative Director, President and CEO, S-RACMO Co., Ltd. | Atsushi Tsuchida |
| Senior officer, Regenerative & Cellular Medicine Business RACTHERA Co., Ltd. | Senior officer, Regenerative & Cellular Medicine Business | Makoto Inoue |
| Senior Medical Officer, Ophthalmology RACTHERA Co., Ltd. Regenerative Medicine Office | Senior Medical Officer, Ophthalmology | Koichiro Manabe |
| Vice President, RACTHERA Co., Ltd. Vice President, Head of Regenerative Medicine Office | Officer, Regenerative & Cellular Medicine Office | Kenji Yoshida |
| Vice President, RACTHERA Co., Ltd. | Senior Director, Business Planning Group, Regenerative & Cellular Medicine Office | Takashi Yoshikawa |
| Vice President, S-RACMO Co., Ltd. Vice President, RACTHERA Co., Ltd. |
Vice President, Head of Regenerative & Cellular Medicine Manufacturing Plant | Hidetaka Ohara |
| Vice President, RACTHERA Co., Ltd. | Senior Director, Tissue and organ regeneration Group, Stem cell engineering Group, Regenerative & Cellular Medicine Kobe Center | Ryo Yamaguchi |
*The following press releases were issued on December 17, 2024 in connection with this matter.
Inquiries from the Press